Blood  Pressure  after  Endovascular  Stroke  Therapy  (BEST) -II 
 
National  Clinical  Trial  (NCT)  Identified  Number:  [STUDY_ID_REMOVED] 
Principal Investigator: [INVESTIGATOR_188671], MBBS  
Version  Number:  v.3.0 
January 5, 2022  
 
 
Summary  of Changes  from  Previous  Version:  
Affected 
Section(s)  Summary  of Revisions  Made  Rationale  
9.1, 9.2, The statistical  considerations  portion  is The changes  are made  in 
9.3, 9.[ADDRESS_222712] -II ii  Table  of Contents  
STATEMENT  OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
1 PROTOCOL  SUMMARY  ................................ ................................ ................................ ...............................  2 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  2 
1.2 Schema  ................................ ................................ ................................ ................................ .................  3 
1.3 Schedule  of Activities  (SoA)  ................................ ................................ ................................ ...............  4 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  5 
2.1 Study  Rationale  ................................ ................................ ................................ ................................ .... 5 
2.2 Background  ................................ ................................ ................................ ................................ ...........  5 
2.3 Risk/Benefit  Assessment  ................................ ................................ ................................ ....................  8 
2.3.1  Known  Potential  Risks  ................................ ................................ ................................ ..... 8 
2.3.2  Known  Potential  Benefits  ................................ ................................ ................................  9 
2.3.3  Assessment  of Potential  Risks  and Benefits  ................................ ................................  9 
3 OBJECTIVES  AND  ENDPOINTS ................................ ................................ ................................ ...............  10 
4 STUDY  DESIGN  ................................ ................................ ................................ ................................ ...........  11 
4.1 Overall  Design  ................................ ................................ ................................ ................................ .... 11 
4.2 Scientific  Rationale  for Study  Design  ................................ ................................ ..............................  12 
4.3 Justification  for Dose  ................................ ................................ ................................ .........................  12 
4.4 End of Study  Definition  ................................ ................................ ................................ ......................  12 
5 STUDY  POPULATION  ................................ ................................ ................................ ................................ . 12 
5.1 Inclusion  Criteria  ................................ ................................ ................................ ................................  12 
5.2 Exclusion  Criteria  ................................ ................................ ................................ ...............................  12 
5.3 Lifestyle  Considerations  ................................ ................................ ................................ ....................  12 
5.4 Screen  Failures  ................................ ................................ ................................ ................................ .. 12 
5.5 Strategies  for Recruitment  and Retention  ................................ ................................ ......................  13 
6 STUDY  INTERVENTION  ................................ ................................ ................................ .............................  14 
6.1 Study  Intervention(s)  Administration ................................ ................................ ................................  14 
6.1.1  Study  Intervention  Description  ................................ ................................ ......................  14 
6.1.2  Dosing  and Administration  ................................ ................................ ............................  14 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ .................  [ADDRESS_222713]  Storage  and Stability  ................................ ................................ .......................  15 
6.2.4  Preparation  ................................ ................................ ................................ ......................  15 
6.3 Measures  to Minimize  Bias:  Randomization  and Blinding ................................ ............................  15 
6.4 Study  Intervention  Compliance  ................................ ................................ ................................ ........  16 
6.5 Concomitant  Therapy  ................................ ................................ ................................ ........................  16 
7 DISCONTINUATION/WITHDRAWAL  ................................ ................................ ................................ ........  16 
7.1 Discontinuation  of Study  Intervention  ................................ ................................ ..............................  16 
7.2 Participant  Discontinuation/Withdrawal  from the Study  ................................ ................................  [ADDRESS_222714] to Follow -Up ................................ ................................ ................................ ...............................  17 
8 STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ................................ ......................  17 
8.1 Endpoint  and other  non-safety  Assessments  ................................ ................................ ................  17 
8.2 Adverse  Events  and Serious  Adverse  Events  ................................ ................................ ...............  18 
8.2.1  Definition  of Adverse  Events  (AE)  ................................ ................................ ................  18 
8.2.2  Definition  of Serious  Adverse  Events  (SAE)  ................................ ...............................  [ADDRESS_222715]  ................................ ................................ .............................  21 
8.2.9  Reporting  of Pregnancy  ................................ ................................ ................................ . 21 
8.3 Unanticipated  Problems  ................................ ................................ ................................ ....................  21 
8.3.1  Definition  of Unanticipated  Problems  (UP)  ................................ ................................ . 21 
8.3.2  Unanticipated  Problem  Reporting  ................................ ................................ ................  21 
8.3.3  Reporting  Unanticipated  Problems  to Participants  ................................ ....................  22 
9 STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ ...........  22 
9.1 Statistical  Hypotheses  ................................ ................................ ................................ .......................  22 
9.2 Sample  Size Determination  ................................ ................................ ................................ ..............  23 
9.3 Populat ions for Analyses  ................................ ................................ ................................ ..................  23 
9.4 Statistical  Analyses  ................................ ................................ ................................ ............................  24 
9.4.1  General  Approach  ................................ ................................ ................................ ..........  24 
9.4.2  Analysis  of the Primary  Endpoint(s)  ................................ ................................ .............  [ADDRESS_222716]  Policy  ................................ ................................ ...............................  32 
10.2 Additional  Considerations  ................................ ................................ ................................ .................  32 
10.3 Abbreviations  ................................ ................................ ................................ ................................ ...... 34 
10.4 Protocol  Amendment  History  ................................ ................................ ................................ ............  36 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  39 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
1  
  STATEMENT  OF COMPLIANCE   
 
The trial will be carried  out in accordance  with International  Conference  on Harmonization  Good 
Clinical Practice (ICH GCP) and the following:  
• United  States  (US) Code  of Federal  Regulations  (CFR)  applicable  to clinical  studies  (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part  
812) 
 
Investigators a nd clinical trial site staff who are responsible for the conduct, management, or 
oversight  of NIH-funded  clinical  trials  have  completed  Human  Subjects  Protection  and ICH GCP 
Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both 
the protocol and the consent form will be obtained before any participant is enrolled.  Any 
amendment  to the protocol  will undergo  review  and approval  by [CONTACT_188703].  In addition, all changes to the consent form will be IRB -approved; a 
determination will be made regarding whether a new consent needs to be obtained from 
participants who provi ded consent, using a previously approved consent form.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
2  
 1.1 SYNOPSIS   
 
 
Title:  Blood  Pressure  after Endovascular  Stroke  Therapy  (BEST) - II 
Study Description:  BEST -II is a prospective,  randomized,  open -label,  blinded -endpoint 
(PROBE), clinical trial where eligible acute stroke patients will be 
randomly assigned (1:1:1) to one of the following systolic blood 
pressure targets: (1) a high target of 180mmHg (control), (2) an 
intermediate target of <160mmHg, and (3 ) a lower target of  
<140mmHg.  The SBP will be maintained  below  the assigned  target 
for 24 hours  after a successful  endovascular  clot retrieval  (EVT).  In 
this stage, we will test the harm of the two intervention arms.  
Objectives:  1) To assess the harm of lo wer SBP targets in successfully EVT - 
treated  stroke  patients  by [CONTACT_188704]’ functional status. 2) To assess the probability of a 
successful future phase 3 trial  
 
Endpoints:  Primary  Endpoints:  1) Final  infarct  volume  at 3612 hours  2) Utility - 
weighted 90 14 -day modified Rankin Score  
Secondary Endpoints: 1) Any hemorrhagic transformation 2) 
Symptomatic  hemorrhagic  transformation  3) Neurological  worsening 
associated with anti -hypertensive treatment 4) Fo llow-up MRI 
perfusion core and penumbra volumes.  
Study Population:  We will include adult (≥18 years) patients undergoing successful 
EVT for an occlusion  in the anterior  cerebral  circulation  large  vessel. 
A total of 120 will be randomized to one of the thre e SBP target 
strategies.  
Phase:  2b 
Description of 
Sites/Facilities 
Enrolling 
Participants: 
Description  of Study 
Intervention:  Study patients will be enrolled at the Vanderbilt University Medical 
Center  for the phase  2b. No centers  outside  of the US will participate 
in this study.  
 
Management of SBP will start immediately after satisfactory 
achievement  of successful  recanalization  to lower  and maintain  SBP 
below  the randomly  assigned  target  for 24 hours.  In the event  where 
SBP values  are above  target,  intravenous  nicardipi[INVESTIGATOR_188672] 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below 
assigned target after 15 minutes, nicardipi[INVESTIGATOR_188673] 2.5 mg/hr every 15 minutes until the target SBP or a maximum 
dose of 15 mg/hr is reached.  
Study Duration:  We project to complete enrollment of initial [ADDRESS_222717] patient.  
Participant  Duration:  9014 days.  1 PROTOCOL  SUMMARY  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222718] -II 
eligibility 
screen  
Eligible  
 
Consent  
mTICI  0-2a 
(~15%)  Recanalization 
status  
Ineligible  mTICI  2b-3 
Randomly  assign 
SBP target  
 180 mmHg  <160  mmHg  <140  mmHg  
if ≥160  if ≥140  if ≥110  
24 hr NIHSS  
36±12  hr brain  MRI 
 
90±[ADDRESS_222719] -II Trial Workflow  
 
 
: Treated with antihypertensive medication; mTICI: Modified 
Thrombolysis  in Cerebral  Ischemia;  MRI:  Magnetic  Resonance 
Image;  mRS:  Modified  Rankin  Score;  NIHSS:  National  Institute 
of Health Stroke Scale; SBP: Systolic Blood Pressure  1.2 SCHEMA  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
4  
  
 
 
Schedule  of Events  
 Prior to 
Enrollment  Enrollment  24 
hours  36 (12) 
hours  Day 7 or D/C 
(whichever 
first) Day 
90 
14 
Screening  & Eligibility  X      
Consent  X      
Randomization   #/X     
Medical  History*   #     
Home  Medications*  #      
Laboratory  Studies*  #      
NIH stroke  scale*  #  #    
Vital Signs*  # # #  #  
CT brain*  X  X    
CT Perfusion*  #      
CTA H&N*  X      
MRI (or CT) brain  (FIV & 
Hemorrhage)*     X   
Nicardipi[INVESTIGATOR_050]*    X    
Labetalol  (if needed)*    X    
Discharge  Summary*      X  
Adverse  Events    X  X  
Serious  Adverse  Events    X  X  
Modified  Rankin  Score*       # 
End of Study       X 
*= Standard -of-Care;  X = Manual  task;  # = Automated  Task;  D/C = Discharge;  CTA H&N 
= CT Angiogram  Head  & Neck;  FIV: Final  Infarct  Volume  1.3 SCHEDULE  OF ACTIVITIES  (SOA)  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
5  
  
 
 
 2.1 STUDY  RATIONALE   
 
A quarter of all annual acute ischemic strokes (AIS) in the [LOCATION_002] are caused by a large 
cerebral  vessel  occlusion  (LVO).[ADDRESS_222720]  morbidity  and mortality  rates  among  all 
AIS etiologies.1,2 Endovascular mechanical thrombectomy (EVT) is a revolutionary AIS 
treatment that rapi[INVESTIGATOR_188674], which is most often a 
blood clot. However, despi[INVESTIGATOR_040] a successful recanalization with restorati on of blood flow, about 
half of the EVT -treated patients remain disabled.3 
 
Blood pressure (BP) after successful EVT -mediated recanalization is a readily modifiable 
parameter that may critically influence patient outcomes. The current guideline recommends 
maintaining systolic BP (SBP) [ADDRESS_222721] -I and other preliminary work, SBP [ADDRESS_222722]-EVT BP management across [LOCATION_002] in a recent survey,13 with <140, <160, and  
≤[ADDRESS_222723], due to legitimate concerns about potentially compromised perfusion and re sultant 
worsening  ischemia,  safety  assessments  of these  lower  BP targets  are obligatory  prerequisites 
to larger efficacy trials.  
 
 2.2 BACKGROUND   
 
2.2.1  Over half of endovascularly -treated stroke patients remain disabled at 90 -days. 
The financial  burden  of ischemic  stroke  is $40.1  billion  annually  in the United  States  and it will 
triple by [CONTACT_2892] 2035.16 Strokes caused by a large vessel occlusion (LVO) contribute to the 
vast majority of ischemic stroke -related morbidity and mortality.17 Endovascular mechan ical 
thrombectomy  (EVT)  has revolutionized  acute  stroke  treatment  by [CONTACT_188705].3 Yet, over half of those  treated  with an EVT remain 
disabled at 90 -days despi[INVESTIGATOR_188675] l clot removal.3 With 
increasing  use of EVT for LVO stroke  treatment,18 measures  to further  improve  outcomes  of this 
devastating type of ischemic stroke is necessary. An important and possibly neuroprotective 
intervention is blood pressure (BP) management following EVT.  
 
2.2.[ADDRESS_222724]  ischemic  bed reperfusion  
Higher systolic BP (SBP)  after recanaliza tion can lead to hyperperfusion. During reperfusion 
after transient LVO in rodent models, cerebral arteries demonstrate impaired in autoregulation 
and fail to maintain  a constant  cerebral  blood  flow over a wide range  of systemic  BP to prevent 
brain injury.19,20 Increased SBP after successful EVT -mediated vessel recanalization following  2 INTRODUCTION  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222725] -EVT Systolic  Blood  Pressure  and Functional  Outcom e 
Study  Year No. of Patients  Study  Variable  Outcome  
Measure  OR with 95% CI 
Mistry  et al. 2017  228 Peak  SBP (continuous 
decrement)  mRS shift 
towards  worse 
outcome  0.98 (0.97,  1.0) 
Goyal  et al. 2017  217 Peak  SBP (10 mmHg 
decrement)  mRS  3-6 0.70 (0.56,  0.87)  
Maier  et al. 2018  168 Peak  SBP (continuous 
decrement)  mRS  3-6 0.96 (0.93,  0.99)  
Mistry  et al. 2019  485 Peak  SBP</=158 
mmHg  mRS  3-6 0.77 (0.48,  1.23)  
Prior  observational  studies8-11 (Table  1) have  shown  that lower  SBP in first 24 hours  after EVT is 
associated with lower likelihood to bad functional outcomes, defined as functional dependence 
or death at 90 days (score of 3 -6 on modified Rankin scale). Specifically, patients had worse 
outcomes if their SBP was higher than [ADDRESS_222726] -EVT BP management  practice  
The 2018  American  Heart/American  Stroke  Association  guidelines  recommend  lowering  SBP to 
[ADDRESS_222727] evidence. No randomized clinical trial has been 
conducted in patients treated with EVT to establish the efficacy of permissive hypertension 
(≤180 mmHg) over lower SBP targets. Not surprisingly, we found in our s urvey of [ADDRESS_222728] -EVT BP target is an  
 
 
 
 

Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
7  
  
individualized  decision  taken  collectively  by a team  of clinicians  involved  in each  patient’s  care. 
There is a lack of expert consensus on the ideal post -EVT BP target (Figure 1).  
Figure  1. Results  of StrokeNET  Survey  of 51 Sites.  A) Who decides  the post endovascular  therapy  (EVT)  blood 
pressure (BP) target? B) What is the target systolic BP post -EVT in patients with successful recanalization?  
 
2.2.[ADDRESS_222729] -EVT BP target  
Evidence based resolution to this anecdotal practice is  urgently needed and  asserted by [CONTACT_941] 
2018  AHA/ASA  guideline  committee  and leaders  of the Stroke  Treatment  Academic  Industry 
Roundtable as a premier question in stroke that needs an urgent answer.14,15,[ADDRESS_222730] -EVT SBP ≤[ADDRESS_222731] -EVT SBP 
targets were the following:  <140 (41%), <160 (21%), and 180 (35%). To capture these most 
commonly utilized post -EVT targets, the BEST -II trial will randomly assign patients to one of 
these three SBP target arms.  
 
2.2.[ADDRESS_222732] -EVT BP. As noted in our survey, 74% of the US institutions use 
nicardipi[INVESTIGATOR_188676],  which  is used  in 16% institutions. 
Both these medications have undergone testing for BP reduction in other acute cerebrovascular 
conditions (e.g the ATACH -2 trial and acute stroke trials) and are deemed safe and feasible 
agents.  Additionally,  both these  agents  are readily  available  across  the institutions  in the US and 
allow a stringent BP control with easy titration. Thus, BEST -II will utilize nicardipi[INVESTIGATOR_188677] -EVT.  
 
2.2.8  Timing  and duration  of initiating  antihypertensive  management  
Our preliminary observational data suggests that antihypertensive management should begin 
immediately  after recanalization.  During  the LVO,  there  is often  a physiological  increase  in BP to 
attempt  to maintain  brain  perfusion.  After  a successful  recanalization  with an EVT,  a physiological  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222733] -I, patients with who 
died or lived with severe disability (mRS 5 -6) had on average the 
highest  SBP throughout  the 24 hrs. In patients  who had a moderate 
disability (mRS 3 -4), the physiological decline of SBP failed  to 
persist  throughout  the [ADDRESS_222734]  of 
the 24 hrs, unlike those who had favorable outcomes (mRS 0 -2) 
(Figure 2).  
 
 2.3 RISK/BENEFIT  ASSESSMENT   
 
 
Risks associated with endovascular mechanical 
thrombectomy: As a part of their clinical care, adult patients with 
anterior LVO stroke undergoing EVT are at a risk for death, coma, 
altered  mental  status  requiring  endotracheal  intubation,  bleeding  in 
the bra in and/or groin, vessel injury, vessel re -occlusion, further 
strokes,  malignant  cerebral  edema,  infection,  condition  that require 
surgical treatment, and long -term cognitive dysfunction among 
several possibilities.  
Risks  associated  with higher  SBP target:  Higher  SBP may lead to hyperperfusion  brain  injury 
and hemorrhage in stroke patients treated with EVT. This may clinically  manifest as a 
neurological decline. Normally, cerebral arteries have the unique autoregulatory capability to 
maintain a constant cerebral blood flow over a wide range of systemic BPs to prevent brain 
injury. During recanalization after transient LVO in ro dent models, cerebral arteries demonstrate 
impaired autoregulation, leading to increased blood flow in response to increased BP.20,21 
Although high SBP values associated with worse outcomes in EVT -treated stroke patients in 
preliminary data, a causal relat ionship remains to be established with a high -level of evidence.  
Risks associated with lower SBP targets: Lower SBP may compromise reperfusion, 
especially  at a microcirculatory  level,  and worsen  ischemia  in stroke  patients  treated  with EVT. 
Additionally, c hronically hypertensive patients may experience systemic complications from 
targeting lower SBP, for example, kidney hypoperfusion. Although lower SBP associated with 
better outcomes in EVT -treated stroke patients in preliminary data, a causal relationship  
remains to be established with a high -level of evidence.  
Risk  associated  with selection  of SBP target  by [CONTACT_1758]:  The above  risks are experienced 
by [CONTACT_188706] -treated stroke patients randomized to higher or lower SBP targets as part of routine 
care and outside of the context of clinical research. Currently, an ideal post -EVT SBP target 
from both safety and efficacy standpoint is unknown. SBP t argets are currently selected 
anecdotally.  In BEST -II, the target  of SBP will be decided  randomly  by [CONTACT_1758].  To ensure  that 
this randomly selected target does not pose additional risk to the patient compared to what 
would have selected by a practitioner  in routine care, if a treating practitioner feels a specific 
SBP target other than that randomly assigned to the patient is required for safe treatment, the 
SBP target for that patient may be modified using a one -page “Target Modification Form”. The  
Figure 2. Time dependent changes 
in the SBP according to [ADDRESS_222735] -I. Lines 
with the ribbon represent a fitted 
generalized additive model ( mean - 
like) with 95% confidence  Interval  of 
all (>17,000) SBP values recorded 
over 24 hrs.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222736] -II trial will only control  choice  of SBP target  when  the perceived  risk associated  with each 
randomly assigned target for an individual patient is equivalent in the treating practitioner’s 
opi[INVESTIGATOR_1649]. Any risks (or benefits) associated wit h each target may be enhanced in the trial setting 
due to higher adherence compared to routine care.  
Risks  associated  with collection  of protected  health  information  (PHI) : Collection  of PHI for 
research involves a small risk for violation of patient confidentiality. To minimize this risk, only 
the minimum amount of PHI needed to conduct the study will be collected. All data collected will 
be generated during clinical care, and no additional d ata will be collected for research. At no 
time will we reveal subject identities in any manner, including research presentation, 
descriptions,  or publications.  All data will be entered  into a secure,  password -protected  REDCap 
database. All patients will be  assigned a unique patient identifier upon enrollment in the study.  
Patient  identifiers  will only be accessible  to the PI [INVESTIGATOR_1238] a select  few research  staff.  Once  the 
study results have been published, all study records will be stripped of any PHI in order to  
maximize patient and surrogate confidentiality.  
 
 
The proposed trial is urgent. Thousands of patients undergo EVT every year in the US, yet, 
sparse evidence exists to guide post -EVT BP management. The primary benefit from the 
proposed research is the generation of data of the highest quality for the safet y of mostly 
commonly  practiced  BP managements  to inform  the optimal  BP management  approach  in EVT- 
treated patients. Results of BEST -II are necessary for the design of larger efficacy trials to 
improve outcomes in half of the successfully EVT -treated acute  ischemic stroke patients that 
remain disabled. Even a small improvement in mortality and disability of these patients could 
translate into a great reduction in stroke -related societal economic burden. The findings of this 
study will also significantly imp rove our understanding of safety, efficacy, and mechanistic 
effects of different post -EVT BP strategies that are all within scope of current practice.  
 
 
 
Every patient in the proposed research would have othe rwise been assigned an SBP target 
without  clear  evidence  for safety  or efficacy.  Patients  participating  in the trial may benefit  from 
participation, to the extent that adherence to one of the assigned SBP targets improves 
outcomes or avoids harm. The minimal risks associated with transferring the selection of the 
SBP target from the treating clinician to the study and violation of c onfidentiality are greatly 
outweighed by [CONTACT_188707].  
The BEST -II trial is a necessary step towards a larger efficacy trial to generate rigorous 
evidence  for optimal  post-EVT BP management  strategy.  With this overarching  goal,  the BEST 
series of studies will standardize future EVT -related research and translate into improved 
outcomes of numerous EVT -treated acute ischemic stroke patients who still remain disabled 
despi[INVESTIGATOR_188678].  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
10  
  
 3 OBJECTIVES  AND  ENDPOINTS   
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION 
FOR  ENDPOINTS  
Primary    
To assess the harm of lower 
SBP targets  in AIS patients  that 
are successfully treated with 
EVT.  
 
To assess the probability of a 
positive  phase -III trial evaluating 
the efficacy  of lower  SBP targets 
at improving functional  
outcomes of EVT -treated 
patients  1) Infarct  volume  on 36 +/-12 hr 
MRI (or CT scan if MRI 
contraindicated)  
2) 9014 -day Utility -weighted 
mRS (UW -mRS) with following 
utility  weights:  mRS  0 - 1.0; mRS 
1 - 0.91; mRS 2 - 0.76; mRS 3 - 
0.65;  mRS  4 - 0.33;  mRS  5 - 0; 
mRS  6 – 0. Concern for potential 
compromised blood 
flow to the ischemic 
brain tissue and 
resulting  increase  the 
infarct volume and 
worse functional 
outcome is the 
primary safety 
concern  for clinicians 
when targeting lower 
SBP in post -EVT 
patients. The 
multiple -primary  
endpoints  are chosen 
to mechanistically 
establish safety of 
lower  BP targets  after 
a successful EVT. 
Additionally, 
preliminary  
evaluation of efficacy 
will be performed 
using the 90 [ADDRESS_222737] 
and remaining  
uncertainty.  
Secondary    
To evaluate the effects of SBP 
targets on intracerebral 
hemorrhage, neurological 
worsening,  and brain  perfusion.  1) Any intracerebral  hemorrhage 
on 36 +/ - 12 hr MRI/CT  
2) Symptomatic  intracerebral  
hemorrhage  on 36 +/- 12 hr 
MRI/CT  To evaluate  the effect 
of BP ta rgets on  
brain perfusion, we  
will evaluate 
incidence  of any and 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
11  
  
OBJECTIVES  ENDPOINTS  JUSTIFICATION 
FOR  ENDPOINTS  
 3) Neurological  worsening 
associated with anti - 
hypertensive treatment  symptomatic 
intracerebral 
hemorrhage 
(measures of 
hyperperfusion) as 
well as follow up MRI 
(or CT) infarct 
volumes (to estimate 
hypoperfusion). We 
will also evaluate the 
frequency of 
neurological 
worsening  associated 
with antihypertensive 
agent to estimate  
immediate safety 
concerns with BP 
lowering in the post - 
EVT setting.  
Feasibility  & Compliance    
To determine  the feasibility  and 
compliance  of maintaining  SBP 
below the randomly assigned 
target in EVT -treated patients  1) Compliance  Outcome  – Hourly 
maximum SBP above target 
from 2-[ADDRESS_222738] treatment 
initiation  
2) Feasibility Outcome – 
Separation  of hourly  maximum 
SBP values between three 
SBP target groups [ADDRESS_222739] -II is a prospective, randomized, open -label, blinded -endpoint (PROBE), clinical trial, in 
which eligible acute stroke patients will be randomly assigned (1:1:1) to one of the following 
systolic blood pressure targets: (1) a high target of 180mmHg (c ontrol), (2) an intermediate 
target  of <160mmHg,  and (3) a lower  target  of <140mmHg.  The SBP will be maintained  below 
the assigned target for 24 hours after a successful endovascular clot retrieval (EVT). We will 
test the harm and efficacy of two intervent ion arms.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222740] null hypothesis of “no harm” and an 
alternative hypothesis of “harm” of lower SBP targets. Failure to reject null hypothesis (one 
tailed  p>0.05)  will establish  a lack of evidence  of “harm”.  Thus,  BEST-II paradoxically  assesses 
safety by [CONTACT_188708]. In other words, we will detect a “lack of evidence of harm” 
rather than “evidence of no harm”.  
 
 4.[ADDRESS_222741]  completed  the study  if he or she has completed  all phases  of 
the study including the 90 14 -day follow -up shown in the Schedule of Activities (SoA), Section  
1.3. The end of the study  is defined  as completion  of the last visit or procedure  shown  in the 
SoA in the trial globally.  
 
 
 
 
 [ADDRESS_222742]  meet  all of the following 
criteria:  
1. Male  or female  adult  patients  (≥ 18 years)  
2. Undergoing  successful  EVT (defined  as mTICI  ≥2b) for an occlusion  in the anterior 
cerebral circulation large vessel (specifically, internal carotid artery and M1 or M2 
segments of the middle cerebral artery).  
 
 5.2 EXCLUSION  CRITERIA   
 
We will exclude patients with comorbid conditions that may require condition -specific BP 
mana gement  such  as those  with 1) a diagnosis  of heart  failure  with ejection  fraction  <30%,  2) 
left ventricular assist device, and 3) extracorporeal membrane oxygenation. Additionally, 
pregnant women and patients enrolled in other clinical trials will also be excluded.  
 
 5.[ADDRESS_222743] -II trial but 
are not subsequently randomly assigned to the study intervention or entered in the study. A 
minimal set of information on demography, screen failure details, eligibility criteria, and any 
serious adverse event (SAE) will be recorded for these patients.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
13  
  
 
Individuals  who do not meet  the criteria  for participation  in this trial (screen  failure)  because  of 
an initial inability to undergo EVT may be rescreened if this decision is revoked. Rescreened 
participants will be assigned the same participant number as for the initial screening.  
 
Of the patients meeting inclusion criteria without meeting the exclusi on criteria will have an 
opportunity to participate in the study. Of these, a total of 120 with successful recanalization 
(defined  as an angiographic  score  of 2b or 3 on the modified  Thrombolysis  in Cerebral  Ischemia 
scale, or mTICI) will be randomized to one of the three SBP target strategies. Patients in whom 
a successful recanalization is not achieved will be followed but not intervened upon. These 
patients will not be considered screen failures.  
 
 5.[ADDRESS_222744] patients based on gender, race, o r ethnicity. The anticipated 
demographics are presented in the table below.  
 
Table.  Gender  and race/ethnicity  of EVT-treated  stroke  patients  since  2012  at Vanderbilt 
University Medical Center.  
 
Male   
Female   
White  Black or 
African 
American   
Asian  Native 
Hawaiian or 
other  Pacific 
Islander  American 
Indian/Alaska 
Native   
Hispanic  
50.1%  49.9%  83.4 12.5%  1% <1% <1% 4.1%  
 
Enrollment  will commence  after receiving  Institutional  Review  Board  approval  for human  subject 
research. All stroke patients amenable to EVT at Vanderbilt present to the emergency room 
prior to being transported to the angiography suite for intervention. Patients will be screened in 
the emergency room or the angiography suite for eligibility  using the study inclusion/exclusion 
criteria by a stroke physician, neuro -interventionist, or study coordinator. Upon meeting 
enrollment criteria, a consent will be obtained electronically using REDCap from the patients or 
their legally authorized represe ntative. The electronic consenting process allows the consenting 
party and study personnel to be on or off site, which is critical given the acute time -frame in 
which stroke patients are treated. Capacity of a potential study subject will be determined by a 
trained study personnel based on the ability to communicate, understand, and ask questions.  
Once  consent  is obtained,  patient  will be randomized  to one of the three  systolic  blood  pressure 
target groups after satisfactorily successful recanalization is a chieved, defined as mTICI ≥2b.  
Study intervention will begin soon after randomization. Members of the study team will be 
available  to answer  any questions  during  recruitment  process  and during  the study  period.  
 
All consecutive stroke patients presenting to Vanderbilt University Medical Center who meet 
inclusion  criteria  without  meeting  exclusion  criteria  will have  an opportunity  to participate  in this 
study. At Vanderbilt University Medical Center, 90 -day follow -up with modified Rankin score is 
obtained via a phone interview by [CONTACT_188709] a 90% success rate. We have 
conservatively accounted for a 15% loss to follow -up for this [ADDRESS_222745] informatio n for the patient and legally authorized representative is  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
14  
 6.1.1  STUDY  INTERVENTION  DESCRIPTION  
6.1.2  DOSING  AND  ADMINISTRATION   
documented within patient’s electronic medical record system and electronic consent form to 
minimize loss to 90 -day follow -up. A 36 12-hr post -EVT MRI scan is performed in all EVT - 
treated  stroke  patients  (unless  contraindicated,  in which  case  a CT scan  is performed).  All EVT- 
treated patients, thus, have either MRI or CT scan as routine care at 36 [ADDRESS_222746] an extensive experience in undertaking investigations that involve 
vulnerable patients,  and we will apply our expertise in minimizing risks for these study 
participants. Other special populations, such as fetuses, neonates, pregnant women, children, 
and prisoners will not be eligible for inclusion  
 
Participants  will not be compensated  in any form for their participation  in the study.  
 
 
 
 6 STUDY  INTERVENTION   
 
 6.1 STUDY  INTERVENTION(S)  ADMINISTRATION   
 
 
Management of SBP will start after randomization  to lower and maintain SBP below the 
assigned target for 24 hours. In the event where SBP values are above target, intravenous 
nicardipi[INVESTIGATOR_188679] 2.5 mg/hr  to lower  the SBP.  If SBP is still not reduced  to below 
assigned target after 15 minutes , nicardipi[INVESTIGATOR_188680] 2.5 mg/hr every 15 
minutes until the target SBP or a maximum dose of 15 mg/hr is reached.  
 
In the event  where  SBP values  are above  the randomly  assigned  target,  intravenous  nicardipi[INVESTIGATOR_188681] 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned 
target after 15 minutes, nicardipi[INVESTIGATOR_188680] 2.5 mg/hr every 15 minutes until 
the target SBP or a maximum dose of 15 mg/hr is reach ed. 
If SBP is above target despi[INVESTIGATOR_188682] [ADDRESS_222747] agent, Hydralazine, will 
be added  at the treating  physician’s  discretion.  Incidence  of the latter  scenario  is anticipated  to 
be exceedingly rare.  
We will only target peak SBP as spontaneous SBP reductions are expected after successful 
recanalization.  However , if anti-hypertensive  medication  is used  to lower  the SBP then we will 
obey the following protocol. In the high target group, if the SBP falls below 160 mmHg, 
nicardipi[INVESTIGATOR_188683] 160 -180 mmHg or nicardipi[INVESTIGATOR_188684]  (BEST) - II Version  3.[ADDRESS_222748]  STORAGE  AND  STABILITY  
6.2.4  PREPARATION   
discontinued.  If the SBP falls below  140 mmHg  in the lower  target  group  of <160mmHg  or below 
110 mmHg in lower target group of <140, nicardipi[INVESTIGATOR_188683] 
140-159 and 110-139, respectively,  or nicardipi[INVESTIGATOR_188685].  Attempts  to increase  the SBP 
will only be made at the dis cretion of the attending physician (e.g. associated neurologic 
worsening).  
 
 
 6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY   
 
 
Both nicardipi[INVESTIGATOR_188686] -of-care for 
BP management and are readily available in the central pharmacy and medication dispensing 
system.  
 
 
 
 
Not Applicable.  
 
 
Nicardipi[INVESTIGATOR_188687].  
 
 
Nicardipi[INVESTIGATOR_188688].  
 
 6.3 MEASURES  TO MINIMIZE  BIAS:  RANDOMIZATION  AND  BLINDING   
 
Randomization: Enrolled patients will be randomized (1:1:1; stratified permuted block 
randomization) after the achievement of recanalization while in the angiography suite using 
REDCap randomization tool integrated within EHR, to one of the following groups where SBP 
will be lowered and maintained for 24 hours after a successful EVT: (1) High SBP target 
(180mmHg;  standard -of-care),  (2) Lower  SBP target  (<160mmHg;  intervention),  and (3) Lower 
SBP target (<140mmHg; intervention).  
Blinding:  Given  the nature  of the experiment,  the treating  neuro -intensivist  and other  neuro -ICU 
staff will not be blinded  to the treatment  group  assignment.  Imaging  outcome  assessment  will be 
performed by a central blinded imaging reader with an adjudication by a blinded 
neuroradiologist.  A blinded stroke coordinator will assess clinical outcomes . 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
16  
  
 6.4 STUDY  INTERVENTION  COMPLIANCE   
 
SBP Monitoring: BP will be monitored in a recumbent position using a BP cuff with the 
following frequency: Every [ADDRESS_222749]  every  30 minutes until 
the end of 24 total hours  after EVT.  Arterial  line and more  frequent  BP measurements  will not be 
required but may be used by [CONTACT_188710].  
Feedback  on SBP Compliance:  Study  personnel  will remotely  monitor  SBP values  in real-time 
8am-5pm Monday through Friday. 10% of the hours during nights and weekends will als o be 
monitored. Real -time monitoring will aid identification of any lags between out -of-range SBP 
values and nicardipi[INVESTIGATOR_188689]. This 
will allow us to identify barriers to SBP target compliance. S tudy personnel will regularly attend 
unit, nursing, and physician meetings to educate clinical personnel, solicit safety concerns, and 
address barriers to SBP target compliance.  
 
 
 6.5 CONCOMITANT  THERAPY   
Not Applicable.  
 
 7 DISCONTINUATION/WITHDRAWAL   
 
 7.[ADDRESS_222750] by [CONTACT_68071]. These 
scenarios  can include  but are not limited  to the following:  1) Neurologic  deterioration  associated 
with anti -hypertensive treatment or permissive hypertension 2) Follow -up radiographic findings 
(e.g. intracerebral hemorrhage on CT scan) requiring more stringent BP control 3) Vessel re - 
occlusion requiring more liberal BP control. These findin gs will be reported as AE or SAEs.  
This can be done using a one -page “Target Modification Form” outlining the rationale for 
modification, new SBP target, and any additional comments. No re -challenge of the randomly 
assigned  SBP target  intervention  will be made.  These  patients  will complete  all study  activities 
including the standard of care 90 14 -day follow -up per the study protocol. All efforts will be 
made to undertake protocol -specified safety follow -up procedures to capture adverse events 
(AE), serious  adverse events (SAE), and unanticipated problems (UPs).  
 
 
 7.2 PARTICIPANT  DISCONTINUATION/WITHDRAWAL  FROM  THE  STUDY   
 
Participants  will have  the right to voluntarily  withdraw  from participation  in the study  at any time 
upon  request.  An investigator  may discontinue  the study  intervention  for the following  reasons:  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
17  
  
• Pregnancy  diagnosed  after enrollment  
• If any clinical  adverse  event  (AE),  laboratory  abnormality,  or other  medical  condition  or 
situation occurs such that continued participation in the study would not be in the best 
interest of the participant  
• Disease  progression  which  requires  discontinuation  of the study  intervention  
• If the participant  meets  an exclusion  criterion  (either  newly  developed  or not previously 
recognized) that precludes further study participation  
• Participant  unable  to receive  study  intervention  for >1.5 hours  following  successful 
recanalization.  
 
The reason  for participant  discontinuation  or withdrawal  from the study  will be recorded  on the 
electronic Case Report Form (CRF). Subjects who sign the informed consent form and are 
randomized  but do not receive  the study  intervention  may be replaced.  Subjects  who sign the 
informed consent form, and are randomized and receive the study intervention, and 
subsequently withdraw, or are withdrawn or discontinued from the study, will not be replaced.  
 
 
 7.[ADDRESS_222751] to follow -up for the primary end -point of UW -mRS if he or 
she is unable to be contact[CONTACT_136589], either via a telephone or an in -person 
meeting  at 90 14-days  after randomization.  A participant  will be considered  lost to follow -up for 
the primary end -point of infarct volume if neither MRI or CT scan is obtained at 36  [ADDRESS_222752]  with the participant  (where  possible,  3 telephone  calls and, if necessary, 
a certified letter to the participant’s last known mailing ad dress or local equivalent methods).  
These  contact  [CONTACT_188711]’s  medical  record  or study  file. 
 
 8 STUDY  ASSESSMENTS  AND  PROCEDURES   
 
 8.1 ENDPOINT  AND  OTHER  NON -SAFETY  ASSESSMENTS   
 
Primary  endpoints  assessment:  
1) 9014 -day Utility -weighted modified Rankin score: An attempt to obtain a modified Rankin 
score is obtained at 90 14 days after the day of admission is made for all stroke patients 
admitted to the Vanderbilt University Medical Center. This atte mpt is made by [CONTACT_188712] - 
coordinator via a phone call or clinic follow -up. The stroke coordinator will be blinded to the 
SBP target assignment. The modified Rankin score (mRS) is an ordinal disability score 
ranging from 0 (no symptoms) to 6 (death). Util ity weights are assigned to this ordinal scale 
for practical applicability since the difference between any two points on the scale is not 
linearly proportional to the difference in ‘value’ placed by [CONTACT_188713]. Thus , to make this scoring system more patient -centered, utility weights 
will be assigned  as follows - mRS  0 - 1.0; mRS  1 - 0.91;  mRS  2 - 0.76;  mRS  3 - 0.65;  mRS  4 
- 0.33;  mRS  5 - 0; mRS  6 – 0 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
18  
 8.2.1  DEFINITION  OF ADVERSE  EVENTS  (AE)  
8.2.2  DEFINITION  OF SERIOUS  ADVERSE  EVENTS  (SAE)   
2) Infarct volume on 36 (±12) -hr MRI or CT scan (FIV): At 36±[ADDRESS_222753] -II include  radiographic,  physical,  and questionnaire  type 
evaluations outlined below:  
• Radiographic  or other  imaging  assessments . 
In addition  to the FIV, the following  imaging  endpoints  will be assessed:  
1) Baseline  CT scan  (standard -of-care):  ASPECT  score  determined  by [CONTACT_188714].  
2) Baseline  CT angiogram  (standard -of-care):  Location  of the large  vessel  occlusion 
determined by [CONTACT_188715] a trained  personnel  as part of the study 
procedure.  
3) Baseline CT perfusion (standard -of-care): CTP will be processed usin g the 
iSchemaview RAPID software to automatically determine the core and penumbra 
volumes  as well as the hypoperfusion  intensity  ratio (HIR;  used  to assess  collateral 
circulation) which will be extracted.  
4) 36 (±12) -hr MRI or CT scan  (standard -of-care):  Presence  or absence  of hemorrhage 
will be determined  by [CONTACT_188716].  In 
case of contraindication to an MRI, a [ADDRESS_222754] scan will be obtained.  
• Physical  examination . NIH stroke  scale  will be calculated  at baseline  and 24 hours  by 
[CONTACT_58403]. Patients  will be closely  monitored  in the Neurological  ICU during  the 
study pr ocedure and any changes in the neurological examination will be rapi[INVESTIGATOR_188690].  
• Laboratory evaluations . Baseline standard -of-care laboratory values of glucose, 
platelet, International Normalized Ratio, Blood Urea Nitrogen, and creatini ne will be 
recorded.  36 (±12)  hr Blood  Urea  Nitrogen  and creatinine  will be obtained  as standard - 
of-care.  
• Administration  of questionnaires  or other  instruments . Baseline  modified  Rankin 
score will be obtained when possible by [CONTACT_188717].  
• Other  clinical  care during  24 hours  of the study  period  and all clinical  care after  24 
hours will be provided according to the American Heart Association/ American Stroke 
Associ ation guidelines.  
 
 
 8.2 ADVERSE  EVENTS  AND  SERIOUS  ADVERSE  EVENTS   
 
An adverse event (AE) will be any untoward medical occurrence for a patient enrolled in BEST - 
II, regardless  of whether  the event  was considered  intervention -related  or not. Events  tracked  as 
clinical outcomes are not considered adverse events.  
 
 
AEs that meet  any of the following  criteria  will be considered  Serious  AEs (SAEs):  
a) Results  in death  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
19  
 
8.2.3  CLASSIFICATION  OF AN ADVERSE  EVENT  
[IP_ADDRESS]   SEVERITY  OF EVENT  
[IP_ADDRESS]   RELATIONSHIP  TO STUDY  INTERVENTION  
[IP_ADDRESS]   EXPECTEDNESS  
8.2.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND 
FOLLOW -UP  
b) Is life-threatening  (defined  as an event  in which  the participant  was at risk of death  at the 
time of event and NOT an event that hypothetically might have caused death if it would 
have been more severe)  
c) Prolongs  existing  hospi[INVESTIGATOR_059]  
d) Results  in persistent  or significant  disability  above  and beyond  what  would  be expected 
for the underlying ischemic stroke.  
e) Results  in a congenital  anomaly  or birth defect  
f) Medical  event  that requires  intervention  to prevent  any of the above  a-e. 
 
 
 
For adverse  events  (AEs)  not included  in the protocol  defined  grading  system,  the following 
guidelines will be used to describe severity.  
 
• Mild – Events  require  minimal  or no treatment  and do not interfere  with the participant’s 
daily activities.  
• Moderate  – Events  result  in a low level of inconvenience  or concern  with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy  or other  treatment.  Severe  events  are usually  potentially  life-threaten ing or 
incapacitating.  
 
All adverse events (AEs) must have their relationship to study intervention assessed by [CONTACT_188718]/her 
clinical judgment. The degree of certainty about causality will be g raded using the categories 
below.  
 
• Related – The AE is known to occur with the study intervention, there is a reasonable 
possibility  that the study  intervention  caused  the AE, or there  is a temporal  relationship 
between the study intervention and event. Re asonable possibility means that there is 
evidence to suggest a causal relationship between the study intervention and the AE.  
• Not Related  – There  is not a reasonable  possibility  that the administration  of the study 
intervention caused the event, there is no temporal relationship between the study 
intervention and event onset, or an alternate etiology has been established.  
 
 
The PI [INVESTIGATOR_21190] (AE) is expected or 
unexpected.  An AE will be considered  unexpected  if the nature,  severity,  or frequency  of the 
event  is not consistent  with the risk information  previously  described  in the literature  for SBP 
lowering in acute cerebrovascular conditions.  
 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
20  
 8.2.5 ADVERSE  EVENT  REPORTING  
8.2.6 SERIOUS  ADVERSE  EVENT  REPORTING   
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the 
attention  of study  personnel  during  study  visits  and interviews  of a study  participant  presenting 
for medical care, or upon review by a study monitor.  
Study personnel wi ll monitor enrolled patients for AEs throughout the trial and follow all AEs 
until they are resolved. All AEs will be recorded on the electronic case report form (eCRF). 
Information  on event  description,  time of onset,  clinician’s  assessment  of severity,  relationship 
to intervention, and time of resolution/stabilization of the event will be collected.  
Any medical condition that is present at the time that the participant is screened will be 
considered  as baseline  and not reported  as an AE. Howeve r, if the study  participant’s  condition 
deteriorates at any time during the study, it will be recorded as an AE.  
 
Changes  in the severity  of an AE will be documented  to allow  an assessment  of the duration  of 
the event at each level of severity to be perfor med.  
 
Study coordinator will record all reportable events with start dates occurring any time after 
informed  consent  is obtained  until 7 (for non-serious  AEs)  or 30 days  (for SAEs)  after the last 
day of study participation.  Events will be followed for outcome information until resolution or 
stabilization.  
 
 
 
All AEs will be recorded  in the eCRF  and communicated  to the PI [INVESTIGATOR_874]  [ADDRESS_222755] (IRB) and DSMB as part of annual review 
process as required.  
 
The BEST -II trial will monitor,  track,  and report  all Clinical  Outcomes  and AEs as required  by 
[CONTACT_156740].  
Clinical Outcomes (not con sidered Adverse Events):  Stroke -related mortality, disability, and 
intracranial  hemorrhage  are expected  clinical  outcomes  for patients  included  in this study  and 
will be tracked and collected as a study outcome on the eCRF and will be included in the 
statistical analysis. For reporting purposes, events listed below will not be reported as AEs 
unless believed to be study related or more severe or prolonged than expected given the 
underlying stroke.  
1. Death  (all deaths  occurring  prior to discharge  be reported  in the eCRF).  
2. Intraparenchymal  intracranial  hemorrhage  without  or without  receipt  of surgical  or 
medical intervention.  
3. Neurological  decline  within  [ADDRESS_222756]-treatment  initiation  (defined  as 4 points  of 
more increase in NIH stroke scale)  
4. Disability  scored  on the modified  Rankin  scale  at 90[ADDRESS_222757]-stroke.  
 
 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222758]  
8.2.9   REPORTING  OF PREGNANCY  
8.3.1  DEFINITION  OF UNANTICIPATED  PROBLEMS  (UP)  
8.3.2  UNANTICIPATED  PROBLEM  REPORTING   
SAEs  will be reported  to the PI [INVESTIGATOR_874]  72 hours  and the PI [INVESTIGATOR_188691], DSMB,  and NINDS 
no later than 7 days of occurrence.  
The study clinician will immediately report to the sponsor any serious adverse event, whether or 
not considered study intervention related and will include an assessment of whether there is a 
reasonable p ossibility that the study intervention caused the event. Study endpoints that are 
serious adverse events (listed in 8.2.5) will be reported in accordance with the protocol unless 
there  is evidence  suggesting  a causal  relationship  between  the study  intervention  and the event. 
In that case, the PI [INVESTIGATOR_188692].  
 
All serious adverse events (SAEs) will be followed until satisfactory resolution or until the  PI 
[INVESTIGATOR_138035].  Other supporting documentation of 
the event  may be requested  by [CONTACT_1201]/DSMB/NINDS  and will be provided  as soon  as possible.  
 
 
Participants  will be informed  about  AEs and SAEs,  and study -related  results  on an individual 
level via an in -person visit prior to discharge or a telephone call after discharge from the 
Vanderbilt University Medical Center.  
 
 
Not Applicable  
 
Not Applicable  
 
 8.3 UNANTICIPATED  PROBLEMS   
 
 
Unanticipated  problems  are those  that involve  risks to participants  or others  to include,  in 
general, any incident, experience, or outcome that meets all of the following criteria:  
 
• Unexpected  in terms  of nature,  severity,  or frequency  given  (a) the research  procedures 
that are described in the protocol -related documents, such as the Institutio nal Review 
Board (IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied;  
• Related  or possibly  related  to participation  in the research  (“possibly  related”  means 
there  is a reasonable  possibility  that the incident,  experience,  or outcome  may have 
been caused by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm 
(including  physical,  psychological,  economic,  or social  harm)  than was previously  known 
or recognized.  
 
 
 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
22  
 8.3.3  REPORTING  UNANTICIPATED  PROBLEMS  TO PARTICIPANTS   
The principal  investigator  [INVESTIGATOR_188693]  (UPs)  to the Vanderbilt  Institutional 
Review Board (IRB). The UP report will include the following information:  
 
• Protocol  identifying  information:  protocol  title and number,  PI’s name,  and the IRB 
project number;  
• A detailed  description  of the event,  incident,  experience,  or outco me; 
• An explanation  of the basis  for determining  that the event,  incident,  experience,  or 
outcome represents an UP;  
• A description  of any changes  to the protocol  or other  corrective  actions  that have  been 
taken or are proposed in response to the UP.  
 
To satisfy  the requirement  for prompt  reporting,  UPs will be reported  using  the following 
timeline:  
 
• UPs that are serious adverse events (SAEs) will be reported to the IRB and to the 
DCC/study  sponsor  within 7 days  of the investigator  becoming  aware  of the event.  
• Any other  UP will be reported  to the IRB and to the DCC/study  sponsor  within  30 days  of 
the investigator becoming aware of the problem.  
 
Not Applicable  
 
 9 STATISTICAL  CONSIDERATIONS   
 
 9.1 STATISTICAL  HYPOTHESES   
 
 
 
Hypothesis 1: A 10 cubic centimeter (cc) increase in the FIV is considered clinically meaningful 
and known to be associated with worse outcome. A 10 cc increase in FIV with each 20 mmHg 
decrease  in SBP equates  to a slope  of 0.5 of a linear  regression  of FIV with SBP.  Therefore,  the 
alternative hypothesis is that the slope of a linear relationship between SBP and FIV is 
numerically greater 0.5. Hence, a significant finding would be evidence that decreasing SBP 
increases FIV beyond a level which is consider ed safe, informing the lower limit for targeting 
SBP for testing in future trials (Figure 1).  
 
 
Hypothesis 2: We consider 0.10 decrease in the UW -mRS scale from 0 (worst outcome) to 1 
(best outcome) as clinically meaningful. A 0.10 decrease on the UW -mRS s cale for every 20 
mmHg decrease in SBP equates to a slope of -0.005 of a linear regression of UW -mRS with 
SBP.  Therefore,  the alternative  hypothesis  is that the slope  of a linear  relationship  between  SBP 
and the UW -mRS numerically less than -0.005, i.e. a larger negative slope. Hence, a significant 
finding would be evidence that decreasing SBP worsens UW -mRS, also informing the lower  
limit for targeting SBP for testing in future trials (Figure 1).  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222759] -I 
data (our prospective, observational, multi -center study), we estimate d the slope for the linear 
relationship  of SBP and the UW-mRS.  From  this model,  we calculated  the standard  deviation  of 
residuals to be 0.[ADDRESS_222760] 80% power using a one -sided test  with the level of 
significance,  alpha,  of 0.[ADDRESS_222761] both these  hypotheses  (Table  1). After  accounting  for a 15% 
loss to follow up for 90 14 -day outcome, our final sample size is 120 patients.  FIV and UW - 
mRS will be treated as continuous variables wit h normal distribution.25 
 
 
 
 
Table  1: Sample  size calculation  
Outcome  Effect  sizea Minimum  Patients  Powerb Attrition  
FIV Linear  10 cc  101 80% 0% 
UW-mRS  
Linear  0.10  101 80% 15% 
Final  Sample  Size=  [ADDRESS_222762]-EVT peak  SBP target;  bone-tailed  =0.05  
 
 
 
 9.3 POPULATIONS  FOR  ANALYSES   

Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
24  
 9.4.1  GENERAL  APPROACH  
9.4.2  ANALYSIS  OF THE  PRIMARY  ENDPOINT(S)   
 
 
Intention -to-Treat (ITT) Analysis Dataset (i.e., all randomized participants) will be used for 
primary analysis. The assigned intervention SBP groups will be used and evaluated, not the 
patients  actual  BP. Thus,  the slopes  of FIV and UW-mRS  will be determi ned using  the patient 
intervention SBP group assignment in regression models.  
 
 
 9.[ADDRESS_222763] harm of the lower SBP targets; therefore, all statistical 
tests  pertaining  to the harm  hypotheses  will be one-tailed  with an alpha  to reject  null hypothesis 
set at 0.05. Strength of evidence (e.g., confidence interva ls around estimates) will be 
emphasized in addition to the level of significance in our reporting. Data will be screened for 
integrity prior to analysis. Statistical assumptions will be tested and appropriate data 
transformations and model adjustments will  be made as needed. If it is determined that the 
proposed statistical plan cannot be conducted after reasonable adjustments, we will revert to 
alternative techniques (such as non -parametric approaches and non -linear modeling) to 
address the study aims.  
 
 
 
 
 
A mixed  effects  linear  regression  model  will be generated  to quantify  the slopes  of FIV and UW- 
mRS with low (<140 and <160 mmHg) and high ( 180 mmHg) SBP targets. The assigned 
intervention SBP groups will be used and evaluated, not the patients actual BP. Thus, the 
slopes of FIV and UW -mRS will be determined using the patient intervention SBP group 
assignment  in regression  models. Rejection  of the null hypothesis  with a significant  alpha  would 
be evidence that decreasing SBP is unsafe. No corrections will be made for multiple hypothesis 
testing (please see below for justification). Covariables for the models for primary outcomes are 
defined a priori. We will adjust FIV for baseline ASPECT score and UW -mRS for baseline UW - 
mRS. We will also adjust analysis for both of the outcomes with the following variables as 
appropriate: age, baseline NIH stroke scale, and collateral circulation (assessed wit h modified 
Tan score), and site (where site will be treated as random effects). Regression diagnostics will 
be conducted on both models (for example, diagnostics for collinearity among predictor 
variables and overfitting). Age and baseline NIH stroke scale  will be treated as continuous 
variables  allowing  for non-linearity  using  cubic  splines  with 3-5 knots  that are not pre-positioned.  
 
 
Justification  for forgoing  multiplicity  correction:  BEST -II is designed  to detect  harm  of lowering 
SBP in successfully EVT -treated acute ischemic stroke patients. In this case, a type II error,  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222764] for 
multiplicity in order to maintain power at the expense of type I error. For example, with 
Bonferroni correction for multiplicity, a p -value less than 0.025 woul d be required for statistical 
significance.  However,  a p-value  of 0.03 for primary  safety  endpoint  (FIV),  increases  concern  for 
harm of the intervention, despi[INVESTIGATOR_188694] -significant after multiplicity correction. By [CONTACT_188719], BEST -II will more rigorously test for harm of the low SBP targets.  
 
 
 
 
 
Interim  analysis  will be planned  after a completed  follow -up of 60 enrolled  patients.  We will 
terminate the study in favor of the alternative hypothesis (evidence of harm) for a p -value  
<0.025.  Trial will not be terminated  early  for efficacy.  No correction  for alpha  (i.e., alpha 
spending) will be made in the final analysis to maintain power.  
 
 
AEs will be coded using the Medical Dictionary for Regulatory Activities. Each AE will be 
counted  once  only for a given  participant.  Severity,  frequency,  and relationship  of AEs to study 
intervention will be presented by [CONTACT_1196] (SOC) and preferred term groupi[INVESTIGATOR_14839].  
Start date, stop date, severity, relationship, expectedness, outcome, and duration will be 
reported  for each  AE. Adverse  events  leading  to premature  discontinuat ion from the study 
intervention and serious AEs will be presented either in a table or a listing.  
 
 
 
 
Interim  analysis  will be planned  after a completed  follow -up of 60 enrolled  patients.  Study  will be 
terminated in favor of the alternative hypothesis of aim 1 (evidence of harm) for a p -value  
<0.025  for a slope  of less than -0.5 for FIV or greater  than 0.005  for UW-mRS.  Trial will not be 
terminated early for efficacy. No correction for alpha (i.e., al pha spending) will be made in the 
final analysis to maintain power.  
 
 
 
 
All attempts will be made to minimize missingness of the data. Any remaining missing data on 
covariates will be imputed using multiple imputations. Missingness of the primary outcomes is 
accounted for in the sample size calculations. However, to determine if missing data on primary 
outcomes  is not at random,  a sensitivity  analysis  will be conducted.  We will fit a model  to predict 
the missing FIV and UW -mRS (this model will not include the treatment variable) and this 
predicted outcome will be used to run an analysis similar to the primary analysis to determine 
the relationship of the treatment group with each outcome variab le. 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
26  
 9.4.7   DESCRIBING  THE FIDELITY  TO INTERVENTION  
10.1.1  INFORMED  CONSENT  PROCESS  
[IP_ADDRESS]  CONSENT/ASSENT  AND OTHER  INFORMATIONAL  DOCUMENTS  
PROVIDED  TO PARTICIPANTS  
[IP_ADDRESS]  CONSENT  PROCEDURES  AND  DOCUMENTATION   
 
 
 
 
Differential effect of SBP groups on each outcome will be determined according to age (as 
continuous  variable),  baseline  ASPECT  score,  collateral  grade,  and reperfusion  grade  using 
interaction terms. In case of a significant interaction, a formal subgroupi[INVESTIGATOR_188695].  An exploratory  subgroup  analysis  according  to ant-hypertensive  use (yes or no) 
prior to admission will be undertaken.  
 
 
 
 
Fidelity to the assigned intervention will be represented both graphically and numerically. We 
will generate temporal profile plots for each patients observed SBP values (color coded 
according to assigned SBP groups) and by p lotting average hourly SBP for each group against 
time.  Further,  we will report  the average  time spent  below  target  for each  group  and the number 
of anti -hypertensives used (% of patients on 1,2,3, or >3 anti -hypertensive agents during the 
study period).  
 
 
 
 [ADDRESS_222765]  them.  The informed  consent  form is 
submitted with this protocol.  
 
 
Informed consent is a process that is initiated prior to the individual’s agreeing to 
participate in the study and continues throughout the individual’s study participation. 
Consent forms will be Institutional Review  Board (IRB) -approved and the participant or 
their surrogate healthcare decision maker will be asked to read and review the 
document. The investigator will explain the research study to the participant or their 
surrogate  healthcare  decision  maker  and answe r any questions  that may arise.  A verbal 
explanation will be provided in terms suited to the participant’s or their surrogate  9.4.6 SUBGROUP  ANALYSIS  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
27  
 10.1.2  STUDY  DISCONTINUATION  AND  CLOSURE   
healthcare  decision  maker’s  comprehension  of the purposes,  procedures,  and potential 
risks of the study and of their rights as research participants.  Participants or their 
surrogate healthcare decision makers will have the opportunity to carefully review the 
written consent form and ask questions prior to signing. The participant s or 
their surrogate  healthcare  decision  makers  will have  the opportunity  to discuss  the study 
with their family or surrogates or think about it prior to agreeing to participate.  
Participants and their surrogate healthcare decision makers will be informed that 
participation is voluntary  and that  they may withdraw from  the study at  any time,  without 
prejudice. A copy of the informed consent document, either physical or electronic, will 
be given to the participants for their records. The rights and welfare of  the participants 
will be protected  by [CONTACT_188720].  
 
All three arms of the BEST -II trial that the participants will be randomized to are 
considered standard of care with a documented equipoise. Any participant undergoing 
successful  recanalization  with mechanical  thrombectomy  could  undergo  blood  pressure 
management similar to any of the arms in practice either at VUMC or other institution 
within the US. Additionally, our prior studies have shown that the blood pressure 
management must started immediately after recanalization to derive ideal benefi t of 
each  arm. On an average,  after the first contact  [CONTACT_6635],  all efforts  are made 
to initiate the thrombectomy  procedure and achieve recanalization as soon as possible.  
 
1. If the participant is cognitively intact and is able to provide consent , the informed 
consent  procedure  will take place  either  in person  or remotely  using  an electronic 
consent form. The study intervention will only be commenced once the 
participant has signed the informed consent form.  
2. If the participant is cognitively impai red at presentation, the study personnel will 
reach  their surrogate  healthcare  decision  maker  to obtain  an informed  consent.  If 
the surrogate healthcare decision maker is remote from the study personnel 
obtaining consent, an electronic consent form can be sent via text message or 
email for their signature.  
3. If the participant  or their legally  authorized  representative  decide  to withdraw  their 
participation in the study, the study intervention will be immediately stopped and 
patient will be provided standard of care as determined appropriate by [CONTACT_188721]. The participant’s data that is collected prior to the withdrawa l 
will be used for research purposes and final analysis of the trial  
 
 
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause.  Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_188722].  If the study  is prematurely  terminated  or suspended,  the Principal  Investigator 
(PI) will promptly inform study participants, the Institutional Review Board (IRB), and sponsor  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
28  
 10.1.3  CONFIDENTIALITY  AND  PRIVACY   
and will provide  the reason(s)  for the termination  or suspension.  Study  participants  will be 
contact[INVESTIGATOR_530], as applicable, and be inform ed of changes to study visit schedule.  
 
Circumstances  that may warrant  termination  or suspension  include,  but are not limited  to: 
• Determination  of unexpected,  significant,  or unacceptable  risk to participants  
• Insufficient  compliance  to protocol  requirements  
• Data  that are not sufficiently  complete  and/or  evaluable  
• Determination  that the primary  endpoint  has been  met 
• Determination  of futility  
 
Study  may resume  once  concerns  about  safety,  protocol  compliance,  and data quality  are 
addressed and satisfy the IRB.  
 
 
 
 
 
Participant  confidentiality  and privacy  is strictly  held in trust by [CONTACT_188723].  This confidentiality  is extended  to cover  the clinical  information  relating  to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence.  
 
All data will be entered into electronic case report forms in a secured, password -protected 
database. The trial will utilize REDCap for data collection, transmission, and storage. REDCap  
is a secure, web -based application for building and managing online d atabases. VUMC 
maintains an institutionally -developed and updated software toolset and workflow methodology 
for electronic  collection  and management  of research  and clinical  trial data.  All study  data will be 
entered via a password -protected REDCap databas e website unique for this study. REDCap 
servers are housed in an institutional, secured data center with regular backup, and all web - 
based information transmission is encrypted. REDCap was developed specifically to comply 
with all HIPAA -Security guideline s and is recommended by [CONTACT_188724]. REDCap has been disseminated for use locally at other institutions 
and currently  supports  >140  academic/non -profit  consortium  partners  and 11,000  research  end- 
users ( www. projectredcap.org ). 
Only the minimum amount of PHI needed to conduct the study will be collected. All data 
collected will be generated during clinical care, and no additional data will be collected for 
research. At no time will we reveal subject identities  in any manner, including research 
presentation, descriptions, or publications. As described above, all data will be entered into a 
secure, password -protected REDCap database. All patients will be assigned a unique patient 
identifier  upon  enrollment  in the study.  Patient  identifiers  will only be accessible  to the PI [INVESTIGATOR_1238] a 
select  few research  staff.  Once  the study  results  have  been  published,  all study  records  will be 
stripped of any PHI in order to maximize patient and surrogate confidentiality.  
The study  participant’s  contact  [CONTACT_188725]. At the end of the study, all records will contin ue to be kept in a secure 
location for as long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor 
requirements  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222766] 
patient  completes  the 9014 -day follow  up and until the time of study  publication.  At the time of 
publication,  a de-identifi ed version  of the database  will be generated.  If a participant  chooses  to 
withdraw their authorization for study staff to access Protected Health Information (PHI), he or 
she may do so by [CONTACT_188726] (the address will be provided on the consent 
form). In this case, actions will be taken to ensure that the  data are properly destroyed and that 
the appropriate documentation is maintained, as is outlined in VUMC manual of standard 
operating procedures.  
 
 
 
 
 
 
 
Principal  Investigator  
[INVESTIGATOR_188671],  MBBS  
Vanderbilt  University  Medical  Center  
[ADDRESS_222767] 
Nashville,  TN, [ZIP_CODE]  
[PHONE_4048]  
[EMAIL_3696]  
 
 
 
A DSMB is appointed for study oversight and consists of physicians experienced in acute 
stroke, neuro -intensive care, and critical care medicine as well as a biostatistical expert. The 
DSMB will review the trial protocol and statistical analysis plan prior  to enrollment of the first 
patient and suggest necessary changes. Following this, they will meet the earlier of hospi[INVESTIGATOR_188696] 30th patient enrolled or [ADDRESS_222768] and manuscript to ensure adequate study reporting.  
 10.1.4  FUTURE  USE OF STORED  SPECIMENS  AND  DATA  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222769]  KEEPI[INVESTIGATOR_1645]  
[IP_ADDRESS]  DATA  COLLECTION  AND  MANAGEMENT  RESPONSIBILITIES   
Clinical  site monitoring  is conducted  to ensure  that the rights  and well-being  of trial participants 
are protected, that the reported trial data are accurate, complete, and verifiable, and that the 
conduct of the trial is in compliance with the currently approved protocol/amendment(s), with 
International Conference on Harmonisation Good Clini cal Practice (ICH GCP), and with 
applicable regulatory requirement(s).  
 
 
Each  clinical  site will perform  internal  quality  management  of study  conduct,  data, 
documentation and completion.  
 
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks  that will be run on the database  will be generated.  The PI [INVESTIGATOR_188697].  
 
Following department written Standard Operating Procedures (SOPs), the monitors will verify 
that the clinical  trial is conducted  and data are generated  and collected,  documented  (recorded), 
and reported in compl iance with the protocol, International Conference on Harmonisation Good 
Clinical Practice (ICH GCP).  
 
 
 
 
 
Data collection will be the responsibility of the clinical trial staff at VUMC under the supervision 
of the PI. The PI [INVESTIGATOR_19760], completeness, legibility, and 
timeliness of the data reported. VUMC uses electronic medical rec ord system for clinical 
documentation and data will be extracted from that and entered in to the REDCap electronic 
case report form. The PI [INVESTIGATOR_188698] (eCRF)  derived  from source  documents  is consistent  with the data recorded  on 
the source documents.  
 
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered into REDCap electronic case report 
form,  a [ADDRESS_222770] to the Enterprise Data 
Warehouse at VUMC, which will be electronically extracted. Quality of this da ta extraction has 
been previously validated with two -physician manual chart review.31,40,41 This data will also be 
used  for compliance  monitoring.  Data  will also be automatically  pulled  from Vanderbilt  University 
Medical Center (VUMC)’s electronic health r ecord system integrated with this project -specific 
REDcap database using the Dynamic Data Pull on Fast Healthcare Interoperability Resources 
(DDP on FHIR) feature.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
31  
 [IP_ADDRESS]  STUDY  RECORDS  RETENTION   
Electronic data elements to be collected : [1] Baseline Characteristics: age; gender; ethnicity; 
admission,  ICU, and discharge  vital signs  (SBP,  diastolic  BP, mean  arterial  BP, pulse);  baseline 
comorbidities (hypertension, diabetes, hyperlipi[INVESTIGATOR_035], stroke, atrial fibrillation, smoking); home 
medications (antiplatelets, anticoagulants, antihypertensives); baseline NIH stroke scale; 
laboratory values (blood serum glucose, international nor malized ratio, platelets) [2] 
Medications: intravenous tissue plasminogen activator administration, in -hospi[INVESTIGATOR_188699]: 
total amount of nicardipi[INVESTIGATOR_188700]; use of any other anti -hypertensive 
agents; vasopressor requirement [3] Clin ical Outcome Measures: 24 -hr NIH stroke scale; in - 
hospi[INVESTIGATOR_39473]; 90 [ADDRESS_222771]  the following elements collected as 
routine clinical care: [1] Time of events such as patient’s  last known well, arrival to emergency 
department,  groin  puncture  to initiate  EVT,  final recanalization,  and intervention  initiation;  [2] all 
adverse events and protocol violations; [3] final mTICI score on angiogram.  
Automated  imaging  data to be collected : All LVO stroke  patients  at VUMC  undergo  baseline  CT 
perfusion studies with automatic, computationally generated calculations of core and penumbra 
volumes and hypoperfusion intensity ratios (to assess collateral circulation) using the 
iSchemaView  RAPID  software.  These  values  will be extracted.  Additionally,  core and penumbra 
volumes on 36±12 -hr MRI perfusion sequence will also be calculated using the iSchemaView 
RAPID software.  
Manual  imaging  data to be collected : [1] Alberta  Stroke  Program  Early  CT score  (ASPECTs)  on 
the baseline brain CT [2] location of vessel occlu sion on baseline CT angiogram [3] presence 
and characteristic  of any hemorrhage  on 36±12 -hr MRI brain  [4] 36±[ADDRESS_222772].  
Validation:  The study  coordinato r will manually  collect  all BP values  within  24-hr post-treatment 
initiation and a 90 14 -day modified Rankin score on 100% of the patients, in addition to all 
variables of data on randomly selected (i.e. 33% [n=40]) patients for validation.  
 
 
 
 
 
Study database will be locked and maintained a read -only mode once data are verified after the 
last patient completes the 90 14 -day follow up and until the time of study publication. At the 
time of publication, a de -identified version of the database will  be generated. If a participant 
chooses to withdraw their authorization for study staff to access Protected Health Information 
(PHI),  he or she may do so by [CONTACT_188727]  (the address  will be provided  on the 
consent form). In this case, actions will be taken to ensure that the data are properly destroyed 
and that the appropriate documentation is maintained, as is outlined in VUMC manual of 
standard operating procedures.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222773]  POLICY   
 
 
A protocol deviation is any noncompliance with the clinical trial protocol, International 
Conference  on Harmonisation  Good  Clinical  Practice  (ICH GCP),  or Manual  of Procedures 
(MOP) requireme nts. The noncompliance may be either on the part of the participant, the 
investigator, or the study site staff. As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483].  
 
These  practices  are consistent  with ICH GCP:  
• 4.5 Compliance  with Protocol,  sections  4.5.1,  4.5.2,  and 4.5.3  
• 5.1 Quality  Assurance  and Quality  Control,  section  5.1.1  
• 5.[ADDRESS_222774] (IRB) per their policies.  
 
 
This study  will be conducted  in accordance  with the following  publication  and data sharing 
policies and regulations:  
 
National Institutes of Health (NIH) Public Access Policy, which ensures that the public has 
access  to the published  results  of NIH funded  research.  It requires  scientists  to submit  final 
peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed  
Central  upon acceptance for publication.  
 
This study  will comply  with the NIH Data  Sharing  Policy  and Policy  on the Dissemination  of NIH- 
Funded Clinical Trial Information and the Clinical Trials Registration and Results Information 
Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results 
information  from this trial will be submitted  to ClinicalTrials.gov.  In addition,  every  attempt will be 
made to publish results in peer -reviewed journals.  Data from this study may be requested from 
other  researchers  1 years  after the completion  of the primary  endpoint  by [CONTACT_188728], 
MBBS at Vanderbilt University Medical Center ([EMAIL_3697]).  
 
 
 
The independence of this study from any actual or perceived influence, such as by [CONTACT_81477], is critical.  Therefo re, any actual conflict of interest of persons who 
have a role in the design, conduct, analysis, publication, or any aspect of this trial will be 
disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be 
required to have  such conflicts managed in a way that is appropriate to their participation in the 
design  and conduct  of this trial. The study  leadership  in conjunction  with the NINDS  will ensure 
that study  group members  to disclose  all conflicts  of interest  and will  establish a  mechanism for 
the management of all reported dualities of interest.  
 
 10.2  ADDITIONAL  CONSIDERATIONS   
None  10.1.10  PROTOCOL  DEVIATIONS  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
33  
  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.[ADDRESS_222775] should  be 
customized for each protocol (i.e., abbreviations not used should be removed and new 
abbreviations used should be added to this list).  
 
AE Adverse  Event  
ANCOVA  Analysis  of Covariance  
CFR Code  of Federal  Regulations  
CLIA  Clinical  Laboratory  Improvement  Amendments  
CMP  Clinical  Monitoring  Plan 
COC  Certificate  of Confidentiality  
CONSORT  Consolidated  Standards  of Reporting  Trials  
CRF Case  Report  Form  
DCC  Data  Coordinating  Center  
DHHS  Department  of Health  and Human  Services  
DSMB  Data  Safety  Monitoring  Board  
DRE Disease -Related  Event  
EC Ethics  Committee  
eCRF  Electronic  Case  Report  Forms  
FDA Food  and Drug  Administration  
FDAAA  Food  and Drug  Administration  Amendments  Act of [ADDRESS_222776] 
IB Investigator’s  Brochure  
ICH International  Conference  on Harmonisation  
ICMJE  International  Committee  of Medical  Journal  Editors  
IDE Investigational  Device  Exemption  
IND Investigational  New Drug  Application  
IRB Institutional  Review  Board  
ISM Independent  Safety  Monitor  
ISO International  Organization  for Standardization  
ITT Intention -To-Treat  
LSMEANS  Least -squares  Means  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MOP  Manual  of Procedures  
MSDS  Material  Safety  Data  Sheet  
NCT National  Clinical  Trial 
NIH National  Institutes  of Health  
NIH IC NIH Institute  or Center  
OHRP  Office  for Human  Research  Protections  
PI [INVESTIGATOR_188701]  (BEST) - II Version  3.[ADDRESS_222777]  Operating  Procedure  
UP Unanticipated  Problem  
US United  States  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
36  
  
 10.4  PROTOCOL  AMENDMENT  HISTORY   
The table below is intended to capture changes of IRB -approved versions of the protocol, 
including  a description  of the change  and rationale.  A Summary  of Changes  table  for the current 
amendment is located in the Protocol Title Page.  
 
Version  Date  Descript ion of Change  Brief  Rationale  
1.0 11/13/[ADDRESS_222778] 
volume will be calculated on 
3612 hours  and modified  Rankin 
Score will be obtained at 90 14 
days.  The changes are made for 
consistency throughout the 
protocol and allow for the 
number  of days  that it might 
take to reach the patient at  
90 days.  
1.0 11/13/[ADDRESS_222779] (only 
successfully  treated  patients) 
for the primary intention to 
treat analysis. In the original 
protocol, the intention was to 
only follow patients with  
unsuccessful  recanalization.  
1.0 11/13/2019  Study intervention will start after 
randomization (which will occur 
after successful  recanalization  is 
achieved per the change 
requested above)  The change requested 
reflects the slight change in 
the trial workflow to allow 
randomization to occur  after 
successful  recanalization  and 
to let the intervention begin  
promptly  after randomization.  
1.0 11/13/[ADDRESS_222780]  led 
to unequal distribution of  
number  of patients  in each 
arm. 
1.0 11/13/2019  Spelling  and language  changes 
are made  Changes  are requested  for 
clarity  
1.0 11/13/2019  It is clarified that the PI, and not 
the DSMB,  will be responsible  for 
determining whether an adverse  
event  is expected  or unexpected.  The changes  requested  will 
allow for faster reporting of 
the AEs to the IRB, as the  
DSMB  meetings  will be 
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
37  
  
   schedule  on a biannual 
basis.  
2.0 10/20/[ADDRESS_222781] 
brain (acquired as routine 
care in all stroke patients) 
can reliably measure this 
infarct burden and advances 
scanning  techniques  such  as 
perfusion  scans  are no better 
at this estimation. Thus to 
simplify trial enrollment 
criteria, the requirement of a 
baseline CT or MR perfusion  
scan  is no longer  required.  
2.0 10/20/20  Follow -up perfusion  outcome 
removed  This outcome is removed as 
it is not routinely  obtained  as 
clinical  care.  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
38  
  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
39  
  
 11  REFERENCES   
 
1. Dozois  A, Hampton  L, Kingston  CW, et al. PLUMBER  Study  (Prevalence  of Large  Vessel 
Occlusion Strokes in Mecklenburg County Emergency Response). Stroke. 
2017;48(12):3397 -3399.  
2. Lima FO, Furie KL, Silva GS, et al. Prognosis of untreated strokes due to anterior 
circulation proximal intracranial arterial occlusions detected by [CONTACT_188729]. JAMA Neurol. 2014;71(2):151 -157. 
3. Goyal  M, Menon  BK, van Zwam  WH, et al. Endovascular  thrombectomy  after large -vessel 
ischaemic stroke: a meta -analysis of individual patient data from five randomised trials. 
Lancet (London, England). 2016;387([ZIP_CODE]):1723 -1731.  
4. Regenhardt  RW, Das AS, Stapleton  CJ, et al. Blood  Pressure  and Penumbral  Sustenance 
in Stroke from Large Vessel Occlusion. Front Neurol. 2017;8:317.  
5. Nour  M, Scalzo  F, Liebeskind  DS. Ischemia -reperfusion  injury  in stroke.  Interv  Neurol.  
2013;1(3 -4):185 -199. 
6. Farooq MU, Goshgarian C, Min J, Gorelick PB. Pathophysiology  and management of 
reperfusion  injury  and hyperperfusion  syndrome  after carotid  endarterectomy  and carotid 
artery stenting. Exp Transl Stroke Med. 2016;8(1):7.  
7. Dalkara T, Arsava EM. Can restoring incomplete microcirculatory reperfusion improve 
stroke outcome after thrombolysis? J Cereb Blood Flow Metab. 2012;32(12):[ADDRESS_222782] mechanical 
thrombecto my and outcomes in large vessel occlusion strokes. Neurology. 
2017;89(6):540 -547. 
9. Maier IL, Tsogkas I, Behme D, et al. High Systolic Blood Pressure after Successful 
Endovascular Treatment Affects Early Functional Outcome in Acute Ischemic Stroke. 
Cerebrova sc Dis. 2018;45(1 -2):18 -25. 
10. Mistry  EA, Mistry  AM, Nakawah  MO, et al. Systolic  Blood  Pressure  Within  24 Hours  After 
Thrombectomy for Acute Ischemic Stroke Correlates With Outcome. J Am Heart Assoc. 
2017;6(5):e006167.  
11. Mistry  EA, Sucharew  H, Mistry  A, et al. Blood  Pressure  after Endovascular  Stroke  Therapy 
(BEST): Final Results  of a Prospective  Multicenter Cohort Validation Study. International 
Stroke Conference; 02/07/2019, 2019; Honolulu, HI.  
12. Elewa HF, Kozak A, Johnson MH, Ergul A, Fagan SC. Blood pressure lowering after 
experimental cerebral ischemia provides neurovascular protection. J Hypert ens. 
2007;25(4):855 -859. 
13. Mistry EA, Mayer SA, Khatri P. Blood Pressure Management after Mechanical 
Thrombectomy for Acute Ischemic Stroke: A Survey of the StrokeNet Sites. J Stroke 
Cerebrovasc Dis. 2018.  
14. Jadhav  AP, Molyneaux  BJ, Hill MD, Jovin  TG. Care  of the Post-Thrombectomy  Patient. 
Stroke.  2018;49(11):2801 -2807.  
15. Liebeskind  DS, Derdeyn  CP, Wechsler  LR, * SXC.  Stair X. Stroke.  2018;49(9):[ADDRESS_222783] CW, et al. Heart Disease and Stroke Statistics -2018 
Update: A Report From the American Heart Associa tion. Circulation. 2018;137(12):e67 - 
e492.  
17. Malhotra K, Gornbein J, Saver JL. Ischemic Strokes Due to Large -Vessel Occlusions 
Contribute  Disproportionately  to Stroke -Related  Dependence  and Death:  A Review.  Front 
Neurol. 2017;8:651.  
18. Smith EE, Saver JL, Cox M, et al. Increase in Endovascular Therapy in Get With The 
Guidelines -Stroke After the Publication of Pi[INVESTIGATOR_188702]. Circulation. 2017;136(24):2303 - 
2310.  
Blood  Pressure  After  Endovascular  Stroke  Therapy  (BEST) - II Version  3.0 
5 January  2022  
40  
  
19. Cipolla MJ, Curry AB. Middle cerebral artery function after s troke: the threshold duration 
of reperfusion for myogenic activity. Stroke. 2002;33(8):2094 -2099.  
20. Cipolla MJ, McCall AL, Lessov N, Porter JM. Reperfusion decreases myogenic reactivity 
and alters middle cerebral artery function after focal cerebral ischemia  in rats. Stroke. 
1997;28(1):176 -180. 
21. Jusufovic M, Sandset EC, Bath PM, Karlson BW, Berge E, Scandinavian Candesartan 
Acute Stroke Trial Study G. Effects of blood pressure lowering in patients with acute 
ischemic stroke and carotid artery stenosis. Int J Stroke. 2015;10(3):354 -359. 
22. Owens WB. B lood pressure control in acute cerebrovascular disease. J Clin Hypertens 
(Greenwich). 2011;13(3):205 -211. 
23. Powers  WJ, Rabinstein  AA, Ackerson  T, et al. 2018  Guidelines  for the Early  Management 
of Patients With Acute Ischemic Stroke: A Guideline for Healthca re Professionals From 
the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46 - 
e110.  
24. Boers  AMM,  Jansen  IGH, Beenen  LFM,  et al. Association  of follow -up infarct  volume  with 
functional  outcome  in acute  ischemic  stroke:  a pooled  analysis  of seven  randomized  trials. 
J Neurointerv Surg. 2018.  
25. Chaisinanunkul N, Adeoye O, Lewis RJ, et al. Adopting a Patient -Centered Approach to 
Primary  Outcome  Analysis  of Acute  Stroke  Trials  Using  a Utility -Weighted  Modified  Rankin 
Scale. Strok e. 2015;46(8):2238 -2243.  
26. Saville  BR, Connor  JT, Ayers  GD, Alvarez  J. The utility  of Bayesian  predictive  probabilities 
for interim monitoring of clinical trials. Clin Trials. 2014;11(4):485 -493. 
27. Broglio KR, Connor JT, Berry SM. Not too big, not too small: a goldilocks approach to 
sample size selection. J Biopharm Stat. 2014;24(3):685 -705. 